Summary

A meta-analysis of 6 randomized trials demonstrated that when compared with aspirin therapy alone, dual antiplatelet therapy beyond 1 year decreased the risk of major adverse cardiovascular events, myocardial infarction, stroke, and cardiovascular death among high-risk patients with previous myocardial infarction while increasing the risk of major bleeding.

  • DAPT
  • dual antiplatelet therapy
  • MACE
  • major adverse cardiovascular event
  • major bleeding
  • MI
  • myocardial infarction
View Full Text